| Oct 29 |
Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy?
|
| Oct 18 |
State Street Corp's Strategic Reduction in Xencor Inc Holdings
|
| Oct 16 |
Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know
|
| Oct 10 |
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
|
| Oct 4 |
Xencor Announces Upcoming Change to Board of Directors
|
| Sep 12 |
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
| Sep 12 |
Xencor: Vudalimab Development Along With Hidden Gem Candidate
|
| Sep 12 |
Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?
|
| Sep 11 |
Xencor stock falls after it prices $175M public offering
|
| Sep 11 |
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
|
